

CALCIUM CHANNEL BLOCKERS

	A	B	D	F	I	Nic	Nif	Nis	V	=
SKIN										
Acneiform eruption / acneiform dermatitis / acneiform rash			[1]					•	[1]	
AGEP			[21]				[3]			?
Anaphylaxis						[1]	[1]			
Angioedema	[6] (6%)		[3]	[1]		[1]	[2]		[3]	✓
Bruise / bruising / contusion / ecchymosis (ecchymoses)			•					•	[1]	
Cutaneous toxicity / skin toxicity	[2]		[2]						[1]	
Dermatitis	(<10%)		[1]				[1]			
Diaphoresis (see also hyperhidrosis)	•	•	[2]	[1]	•		[2]	•	[2]	✓
Eczema / eczematous reaction / eczematous eruption	[2]		[1]							
Edema / fluid retention (see also peripheral edema)	[22] (5–14%)	(<10%)	[4] (<10%)	[1]	[6] (7%)	•	[3]	[1]	[1]	✓✓
Erythema			[2]	•			[2]			
Erythema multiforme	[2]		[11] (31%)				[5]		[4]	?
Erythema nodosum							[2]		[1]	
Erythromelalgia / erythermalgia			[1]			[4]	[6]		[2]	
Exanthems	[2]		[17] (31%)	[2]	[1]		[9]	[1]	[8]	✓
Exfoliative dermatitis			[6]				[5]	•	[2]	
Facial edema	[1]			•			•	•		
Flushing / rubefaction	[5] (<10%)		[6] (<10%)	[10] (44%)	[9] (10%)	[2] (6%)	[9] (44%)	[1] (13%)	[4] (<7%)	✓
Hyperkeratosis			[1]						[2]	
Hypersensitivity	[1]		[2]							
Lichenoid eruption / lichenoid reaction			[1]				[3]			
Linear IgA	[1]								[1]	
Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))	[1]		[5]				[3]		[2]	
Peripheral edema (see also edema)	[47] (34%)	•	[1] (5–8%)	[6] (22%)		[2] (7%)	[12] (6%)	[6] (22%)	[1] (<10%)	✓

A Amlodipine; B Bepridil; D Diltiazem; F Felodipine; I Isradipine; Nic Nicardipine; Nif Nifedipine; Nis Nisoldipine; V Verapamil

	A	B	D	F	I	Nic	Nif	Nis	V	=
Petechiae	[1]		•					•		
Photosensitivity	[1]		[12]				[5]		[4]	
Pigmentation	[2]		[10]					•		
Pruritus (itching)	[3]		[6]	•	[1] (6%)		[3]	•	[6]	✓
Pseudolymphoma	[1]		[1]							
Purpura	[2]		[3]	[1]			[3]		[1]	✓
Pustules / pustular eruption			[2]					•		
Rash	(<10%)	[1]	[4]	•	•	[3]	[2]	•	[2]	✓✓
Stevens-Johnson syndrome	[2]		[6]				[5]		[5]	
Telangiectasia	[6]			[2]			[2]			
Ulcerations							[1]	•		
Urticaria / hives	[1]		[5]	[1]	•	[3]	[7]	•	[5]	✓
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)	[2]		[6]				[4]		[2]	
Xerosis / xeroderma (see also dry skin)	•							•		
HAIR										
Alopecia / hair loss	•		[2]				[4]	•	[5]	✓
Hair pigmentation							[1]		[1]	
NAILS										
Nail dystrophy			[1]				[1]		[1]	
MUCOSAL										
Gingival hyperplasia / gingival hypertrophy / gingival enlargement / gingival overgrowth	[40] (31%)		[10] (21%)	[6] (2-10%)	[1]	[2]	[76] (75%)	•	[10] (19%)	✓
Oral ulceration (see also aphthous stomatitis / aphthous ulcer / aphtha)			[1]					•	[1]	
Xerostomia (dry mouth)	[1]	[2] (<10%)	[2]	[1]	•	•	•	•	•	✓✓

A Amlodipine; **B** Bepridil; **D** Diltiazem; **F** Felodipine; **I** Isradipine; **Nic** Nicardipine; **Nif** Nifedipine; **Nis** Nisoldipine; **V** Verapamil

This table highlights skin, hair, nails, and mucosal adverse drug reactions. Other adverse drug reactions are listed in the text under individual drugs classified as calcium channel blockers.

The following conventions are used in the table:

- reaction noted (package inserts);
- [3] number of published reports of a reaction;
- (8%) highest incidence that has been noted or reported;
- ? 20 reports or over, or an incidence of 20% or over, recorded for this reaction for a minority of drugs in the class;
- ✓ at least half the drugs in the class selection have this reaction noted or reported;
- ✓✓ all drugs in the class selection have this reaction noted or reported.

Note: Drug reactions noted or reported for only one drug are omitted in this table.